欧林生物：目前公司已就第二适应症压疮完成与国家药品监督管理局药品审评中心（CDE）的临床前沟通交流

Core Viewpoint - The company has completed preclinical communication with the National Medical Products Administration (NMPA) regarding a second indication for pressure ulcers and is currently refining related research [1] Group 1 - The company is in the process of finalizing the clinical trial protocol, which will require further communication with the NMPA before submitting for clinical approval [1] - The company anticipates submitting the clinical application this year [1]